Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy Life Science Investing
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Life Science Investing
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA Life Science Investing
DBV Technologies Files At-The-Market Prospectus for Up to $150 Million of Sales Life Science Investing
Allergan Aesthetics receives approval for Boey® , for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients Pharmaceutical Investing
PRINCIPAL TECHNOLOGIES ANNOUNCES PRIVATE PLACEMENT FINANCING IN CONNECTION WITH OXFORD LICENCE AGREEMENT Technology Investing
DBV Technologies Announces the Filing of its 2026 Half-Year Report - Conditions for Accessing or Consulting the Report Life Science Investing
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Life Science Investing
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award Pharmaceutical Investing
